Effects of Alantolactone on Stemness Genes Expression and Epithelial-Mesenchymal Transition (EMT) in Breast Cancer via STAT3 Suppression / Shiva Gholizadeh-Ghaleh Aziz, Saiedeh Kashefi, Naser Khalaji
Background: To reduce the side effects of conventional chemotherapy drugs, new herbal remedies, such as alantolactone, can be used. Objective: We evaluated the association between stemness and EMT (Epithelial- Mesenchymal Transition) process in triple-negative breast cancer cells treated with alantolactone that targets STAT3. Methods: The MDA-MB-231 cell line was used as one of the triple-negative breast cancer cell lines. MTT assay was used to evaluate cell viability and alantolactone dose at threetime points of 24, 48, and 72 hours, and three doses, i.e., 1, 0.1, and 0.01 μM of alantolactone were used to evaluate cellular behavior in proliferative and invasion pathways, respectively. A scratch test was also performed to evaluate the invasive power of cancer cells. Real- time PCR was used to evaluate the expression of regular genes by cancerous cell proliferation, STAT3 NANOG, SOX-2, and E-cadherin metastasis. Results: It was observed that increasing the dose of alantolactone decreased proliferation and metastasis rate. The three doses selected for the cell culture study did not differ significantly from the control group regarding apoptosis-inducing abilities at desired time intervals. Expression of SOX-2, STAT3, and NANOG in the treated cells decreased with increasing dose of the alantolactone, whereas expression of E-cadherin was found to be increased. Conclusion: Alantolactone through the STAT3 signaling pathway affects the expression of E-cadherin, NANOG, and SOX2 genes, inhibiting the EMT process and subsequent stemness, and may potentially be used in therapeutics for cancer patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Current pharmacogenomics and personalized medicine - 19(2022), 1, Seite 10 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Aziz, Shiva Gholizadeh-Ghaleh [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Umfang: |
1 Online-Ressource (10 p) |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
KFL011175753 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL011175753 | ||
| 003 | DE-627 | ||
| 005 | 20231128080357.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230613s2022 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)KFL011175753 | ||
| 035 | |a (KFL)prod_DARH_.03CC5CF3C0D3186A940FA2905F85ADCBE8E7FAE9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Aziz, Shiva Gholizadeh-Ghaleh |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effects of Alantolactone on Stemness Genes Expression and Epithelial-Mesenchymal Transition (EMT) in Breast Cancer via STAT3 Suppression |c Shiva Gholizadeh-Ghaleh Aziz, Saiedeh Kashefi, Naser Khalaji |
| 264 | 1 | |c 2022 | |
| 300 | |a 1 Online-Ressource (10 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Background: To reduce the side effects of conventional chemotherapy drugs, new herbal remedies, such as alantolactone, can be used. Objective: We evaluated the association between stemness and EMT (Epithelial- Mesenchymal Transition) process in triple-negative breast cancer cells treated with alantolactone that targets STAT3. Methods: The MDA-MB-231 cell line was used as one of the triple-negative breast cancer cell lines. MTT assay was used to evaluate cell viability and alantolactone dose at threetime points of 24, 48, and 72 hours, and three doses, i.e., 1, 0.1, and 0.01 μM of alantolactone were used to evaluate cellular behavior in proliferative and invasion pathways, respectively. A scratch test was also performed to evaluate the invasive power of cancer cells. Real- time PCR was used to evaluate the expression of regular genes by cancerous cell proliferation, STAT3 NANOG, SOX-2, and E-cadherin metastasis. Results: It was observed that increasing the dose of alantolactone decreased proliferation and metastasis rate. The three doses selected for the cell culture study did not differ significantly from the control group regarding apoptosis-inducing abilities at desired time intervals. Expression of SOX-2, STAT3, and NANOG in the treated cells decreased with increasing dose of the alantolactone, whereas expression of E-cadherin was found to be increased. Conclusion: Alantolactone through the STAT3 signaling pathway affects the expression of E-cadherin, NANOG, and SOX2 genes, inhibiting the EMT process and subsequent stemness, and may potentially be used in therapeutics for cancer patients | ||
| 700 | 1 | |a Kashefi, Saiedeh |e verfasserin |4 aut | |
| 700 | 1 | |a Khalaji, Naser |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current pharmacogenomics and personalized medicine |d Sharjah : Bentham, 2008 |g 19(2022), 1, Seite 10 |h Online-Ressource |w (DE-627)KFL000006556 |w (DE-600)2424232-9 |w (DE-576)30683636X |x 1875-6913 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2022 |g number:1 |g pages:10 |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/bentham-ejournals-pharmazie/www.eurekaselect.com/openurl/content.php?genre=article&issn=1875-6921&volume=19&issue=1&spage=21 |m X:KFL |x Verlag |y FID Access |z lizenzpflichtig |
| 912 | |a ZDB-1-BEJ | ||
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_DARH_03 | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2022 |e 1 |h 10 | ||